• Arriva Pharmaceuticals, of Amsterdam, the Netherlands, completed a financing of $6 million led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. The funds will be used to continue development of recombinant alpha-one antitrypsin for hereditary emphysema, which is now in a Phase IIb trial.

• Pro-Pharmaceuticals Inc., of Newton, Mass., closed its registered direct offering of common stock and warrants, receiving proceeds of about $3.5 million. That funding is expected to support work on Davanat, which recently generated positive Phase II data in colorectal cancer patients, and on its fibrosis compounds.

• TyRx Pharma Inc., of Monmouth Junction, N.J., raised $25 million in a venture capital round led by Clarus Ventures and co-led by Pappas Ventures. Those funds are intended to help the company, which develops implantable drug-device products, to transition from development stage to commercialization. Jeffrey Leiden and Scott Requadt, both of Clarus, and Arthur Pappas, of Pappas Ventures, will join TyRx's board.